Bajaj NS, et al. - Via performing trial sequential and cumulative meta-analyses, researchers assessed the aggregate effectiveness of extended-duration thromboprophylaxis (EDT) on clinically relevant endpoints, and ascertained the robustness of efficacy signals balanced against the safety of the EDT strategy. The duration of EDT ranged from 24–47 days across 40,247 patients from 5 randomized clinical trials. Investigators found that using an EDT strategy for a 4 to 6-week period of post-hospital discharge reduced symptomatic or fatal VTE events at the expense of increased risk of major or fatal bleeding.